TROY MCCURRY: Open Payments
NPI 1255386520 · GAFFNEY, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$359 in 17 payments from 14 companies in 2025. Trend: 2023 $275 · 2024 $200 · 2025 $359
Food & beverage: $359
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $60 |
| Lilly USA, LLC | 2 | $39 |
| Dexcom, Inc. | 1 | $29 |
| Neurocrine BioSciences, Inc. | 1 | $26 |
| Ardelyx, Inc. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Antares Pharma, Inc. | 1 | $21 |
| AstraZeneca Pharmaceuticals LP | 1 | $21 |
| GlaxoSmithKline, LLC. | 1 | $20 |
Products named: Dexcom G6 Transmitter, INGREZZA, IBSRELA, Auvelity, HETLIOZ, VIBERZI, QULIPTA, ZEPBOUND.
Industry payments across SC — which companies pay providers there.
